SAMRATPH

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Samrat Pharmachem latest dividend payout ratio is 4.34% and 3yr average dividend payout ratio is 6.83%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Short Term Loans & Advances

Balance sheet of Samrat Pharmachem is strong. It shouldn't have solvency or liquidity issues.

The profit is oscillating. The profit of Samrat Pharmachem is ₹4.82 Crs for TTM, ₹7.11 Crs for Mar 2025 and ₹2.16 Crs for Mar 2024.

Yes, The net debt of Samrat Pharmachem is increasing. Latest net debt of Samrat Pharmachem is ₹9.63 Crs as of Mar-25. This is greater than Mar-24 when it was -₹10.96 Crs.

Samrat Pharmachem is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Samrat Pharmachem is 18.65, while 3 year average PE is 18.13. Also latest EV/EBITDA of Samrat Pharmachem is 12.82 while 3yr average is 26.04.

Samrat Pharmachem has given better returns compared to its competitors. Samrat Pharmachem has grown at ~17.32% over the last 7yrs while peers have grown at a median rate of 5.89%

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Samrat Pharmachem is 49.09% and last quarter promoter holding is 49.09%.

There is Insufficient data to gauge this.